Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Topiramate
Drug ID BADD_D02247
Description Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines.[A175249] It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults.[A188309,L10544] Since 2012, the extended-release formulation has been approved in combination with [phentermine] for chronic weight management therapy in adults.[L10550] Characteristics that distinguish topiramate from other antiepileptic drugs are a monosaccharide chemical structure containing a sulfamate, and 40% of its mass accounted for by oxygen.[A175249] Interestingly, topiramate was discovered by chance when attempts were made to formulate a novel antidiabetic drug.[A188330]
Indications and Usage Topiramate is indicated for the following conditions: 1)Monotherapy for partial onset or primary generalized tonic-clonic seizures for patients 2 years of age and above 2)Adjunctive therapy for partial onset seizures or primary generalized tonic-clonic seizures for both adult and pediatric patients above 2 years old 3)Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients above 2 years of age 4)Prophylaxis of migraine in children 12 years of age and older and adults.[L10544] Topiramate is also used off-label as an adjunct therapy for weight management[L10550] and for mood disorders.[A188312]
Marketing Status approved
ATC Code N03AX11
DrugBank ID DB00273
KEGG ID D00537
MeSH ID D000077236
PubChem ID 5284627
TTD Drug ID D07VDZ
NDC Product Code 72603-121; 72603-123; 80425-0195; 0480-2357; 11014-0134; 11014-0136; 11014-0149; 12502-4677; 51927-0149; 10370-365; 66039-806; 47335-707; 47335-710; 50458-645; 51655-608; 61919-318; 61919-439; 62756-707; 65862-173; 68382-769; 68462-370; 70518-1937; 70518-2322; 70518-2419; 71205-187; 71335-0325; 71335-1143; 71610-493; 76282-280; 76420-279; 80425-0092; 11014-0145; 0904-6929; 12658-0410; 51927-4671; 10370-367; 10370-368; 29300-116; 31722-181; 43063-734; 50090-5853; 50458-640; 61919-679; 61919-823; 61919-883; 63187-228; 68084-342; 68382-004; 69097-124; 70518-3067; 70771-1315; 70771-1659; 71205-819; 71335-1147; 0615-8139; 76282-279; 0832-1075; 83008-012; 11014-0147; 11014-0306; 0904-6928; 38779-2443; 51927-0294; 53104-7532; 64162-0339; 16571-708; 43063-605; 43353-697; 51655-429; 55700-217; 62756-712; 63187-283; 65841-650; 65862-174; 68382-139; 68382-141; 68462-110; 68788-7468; 69097-819; 70518-2104; 70518-2391; 70518-2753; 70518-2899; 70518-3460; 71205-202; 71335-0548; 71335-1116; 53808-1132; 68382-138; 68462-374; 69097-122; 70518-0233; 76420-276; 80425-0208; 0832-1073; 83008-011; 50379-0007; 51552-1206; 0093-7336; 29300-118; 31722-183; 50090-5309; 52652-9001; 0245-1073; 60760-577; 61919-369; 61919-824; 63187-059; 63187-773; 65841-651; 65862-171; 68071-3012; 68084-343; 68462-153; 69097-817; 0480-2356; 70518-1180; 70518-1718; 70710-1041; 70710-1043; 71205-214; 0615-8138; 72603-120; 76282-281; 76420-280; 0832-1072; 11014-0146; 65841-134; 16571-705; 16571-707; 17772-101; 29300-115; 43063-729; 43063-998; 50458-641; 50458-642; 51655-606; 62756-711; 63187-963; 63629-4947; 65841-652; 65862-172; 68382-864; 70710-1042; 70771-1656; 71205-233; 71335-9727; 80425-0214; 80425-0288; 11014-0110; 11014-0135; 11014-0137; 17205-096; 16571-706; 31722-182; 43602-457; 50458-639; 0245-1071; 0245-1072; 55154-7142; 62756-710; 63187-060; 63187-479; 63187-696; 63187-801; 68084-345; 68788-7351; 70518-2517; 70518-3758; 70771-1317; 70771-1657; 70771-1658; 71335-0487; 71335-1684; 72603-124; 72789-004; 76282-278; 76420-278; 11014-0148; 10370-366; 43353-696; 50090-3926; 50458-647; 51655-746; 55700-596; 55700-995; 60760-094; 63187-118; 63629-6871; 65841-648; 68071-4760; 68462-109; 68462-373; 68788-7568; 69097-123; 0480-2359; 70518-1196; 70518-1503; 70771-1316; 71610-485; 72603-122; 0832-1071; 0832-1074; 11014-0305; 49452-7827; 65267-103; 65862-383; 71052-315; 31722-184; 43063-612; 43063-735; 43063-997; 0245-1075; 55700-894; 61919-212; 63187-077; 63187-758; 65841-647; 65841-649; 68084-344; 68382-140; 68382-863; 68462-108; 68788-7460; 69097-125; 69097-818; 0480-2358; 70518-0887; 70518-1953; 70518-2001; 70518-2498; 70710-1039; 70771-1660; 71205-195; 71335-0337; 71335-0925; 71610-486; 0615-8140; 11014-0307; 65977-0008; 17772-102; 17772-104; 43602-460; 45865-551; 47335-711; 47335-712; 51655-848; 0245-1074; 53002-1547; 55700-226; 55700-227; 68382-005; 68462-371; 68462-372; 69097-816; 70518-0625; 70518-2955; 70710-1040; 71610-492; 80425-0202; 11014-0308; 53747-097; 65129-1024; 65977-0095; 17772-103; 0093-7335; 29300-117; 43353-695; 43602-458; 43602-459; 53808-1131; 55154-7146
UNII 0H73WJJ391
Synonyms Topiramate | 2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate | Epitomax | McN 4853 | McN-4853 | McN4853 | USL255 | Topamax
Chemical Information
Molecular Formula C12H21NO8S
CAS Registry Number 97240-79-4
SMILES CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sinus bradycardia02.03.03.0090.000251%
Sinusitis22.07.03.007; 11.01.13.005--
Skin discolouration23.03.03.005--Not Available
Skin disorder23.03.03.007--Not Available
Skin erosion23.07.03.0020.000101%Not Available
Skin hyperpigmentation23.05.01.0030.000050%
Skin odour abnormal23.03.03.0120.000050%
Sleep disorder19.02.04.0010.000794%Not Available
Sluggishness08.01.01.0040.000437%Not Available
Social avoidant behaviour19.05.01.0070.000075%Not Available
Somnambulism19.02.03.006; 17.15.02.0040.000201%Not Available
Somnolence19.02.05.003; 17.02.04.0060.004790%
Speech disorder19.19.02.002; 17.02.08.003; 22.12.03.0270.000985%Not Available
Staring19.01.01.003--Not Available
Status epilepticus17.12.03.0050.000503%Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.01.045--
Stillbirth18.01.02.002; 08.04.01.0060.000075%Not Available
Stomatitis07.05.06.005--
Strabismus17.17.01.009; 06.05.02.004--Not Available
Stupor19.02.05.004; 17.02.04.0070.000050%Not Available
Suicidal ideation19.12.01.0030.001302%
Suicide attempt19.12.01.0040.000779%
Swelling face08.01.03.100; 23.04.01.018; 10.01.05.018--Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.0040.000101%Not Available
Tachycardia02.03.02.0070.000538%Not Available
Tearfulness19.15.02.0050.000312%Not Available
Tension19.06.02.005--Not Available
Tension headache19.24.01.009; 17.14.01.0040.000075%Not Available
Testicular disorder21.13.01.002--
The 17th Page    First    Pre   17 18 19 20 21    Next   Last    Total 27 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene